The HPV16 CTL epitopes identified in this study, in combination with blockade of HPV + HNSCC-specific PD-1/IDO-1 checkpoints, may be useful for targeted immunotherapy. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.